Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Primary Objectives:

- To determine the safety and tolerability of BKM120 in combination with weekly
nabpaclitaxel (Abraxane®) in patients with a recurrent solid tumor and in particular a
recurrent endometrial or ovarian cancer.

- To determine the MTD and DLT of BKM120 in combination with weekly nabpaclitaxel
(Abraxane®) thereby establishing the recommended phase II dose.

Secondary Objectives:

- Obtain pilot data on the clinical tumor response utilizing RECIST criteria of BKM120 in
combination with weekly nabpaclitaxel (Abraxane®) in patients with a history of
recurrent endometrial or a recurrent ovarian cancer.

- To determine the progression free survival (PFS) of patients treated with BKM120 and
nabpaclitaxel (Abraxane®) and a history of recurrent endometrial or ovarian cancer.

- To explore molecular markers that my serve as potential molecular predictors of
response including PIK3CA, mTOR, KRAS, PTEN and p53 mutations as well as amplification
of ErbB2.

- To test the predictive value of PIK3CA and KRAS mutations in predicting response to
this regimen in women diagnosed with a recurrent endometrial or ovarian cancer.

Inclusion Criteria:

- Age ≥ 18 years with a recurrent solid tumor in the Phase I portion of the trial or in
the Phase II portion of the trial a recurrent endometrial or ovarian cancer, not
amenable to treatment by surgery, radiotherapy or chemotherapy.

- ECOG performance status £ 2

- Patients must have at least one site of measurable disease defined by RECIST 1.1
criteria. If the patient has received prior radiation therapy one measurable lesion
must be outside the irradiated field. Lesions within an irradiated field will be
followed as non-target lesions and considered evaluable. If the only site of
measurable disease is within a previously irradiated field then 6 months must have
elapsed between the completion of radiation therapy and entry on study to be
considered measurable.

- Patients with a recurrent ovarian cancer must have received at least one prior
platinum containing regimen.

- Patients diagnosed with a platinum sensitive ovarian cancer may be enrolled if they
will no longer benefit from treatment with a platinum agent as determined by their
physician or it would be detrimental to treat the patient with a platinum agent due
to underlying medical problems.

- Adequate bone marrow function as shown by: ANC ≥ 1.0 x 109/L, Platelets ≥ 100 x
109/L, Hgb > 9 g/dL

- Total calcium (corrected for serum albumin) within normal limits (biphosphonate use
for malignant hypercalcemia control is not allowed)

- Magnesium within normal limits for the institution.

- Potassium within normal limits for the institution

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal
range (or ≤ 3.0 x upper limit of normal (ULN) if liver metastases are present)

- Serum bilirubin within normal range. For patients with liver metastases, serum
bilirubin ≤ 1.5 x ULN. For patients with well documented Gilbert Syndrome total
bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range. )

- Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

- Negative serum pregnancy test within 72 hours before starting study treatment in
women with childbearing potential defined as sexually mature women who have not
undergone a hysterectomy or who have had amenorrhea for at least 12 consecutive
months or women who have had six months of spontaneous amenorrhea with serum FSH
levels > 40 mIU/mL and estradiol < 20 pg/mL.

- Patients with Grade 3 or greater peripheral neuropathy.

- Ability to sign informed consent

- INR ≤ 1.5

Exclusion Criteria:

- Patients who have received prior treatment with a P13K inhibitor.

- Patients who have received prior treatment with Nabplaclitaxel Abraxane®.

- Patients with a known hypersensitivity to BKM120 or to its excipients

- Patients with symptomatic brain metastases are excluded. However, patients with
asymptomatic CNS metastases may participate in this trial. The patient must have
completed any prior local treatment for CNS metastases > 28 days prior to study entry
including radiotherapy or surgery. Patients receiving steroids for CNS metastases may
not participate on this study.

- Patients with acute or chronic liver disease, renal disease or pancreatitis

- Patients with the following mood disorders as judged by the Investigator,
Sub-Investigator or a psychiatrist, or as a result of patient's mood assessment
questionnaire:

- Medically documented history of or active major depressive episode, bipolar
disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of
suicidal attempt or ideation, or homicidal ideation (immediate risk of doing
harm to others) or patients with active severe personality disorders (defined
according to DSM- IV) are not eligible. Note: for patients with psychotropic
treatments ongoing at baseline, the dose and the schedule should not be modified
within the previous 6 weeks prior to start of study drug.

- Meets the cut-off score of ≥ 12 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7
mood scale, respectively, or selects a positive response of "1, 2, or 3" to
question number 9 regarding potential for suicidal thoughts in the PHQ-9
(independent of the total score of the PHQ-9)

- Patients with diarrhea ≥ CTCAE 4.0 grade 2

- Patient has active cardiac disease including any of the following:

- Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Grated
acquisition (MUGA) scan or echocardiogram (ECHO)

- QTc > 480 msec on screening ECG (using the QTcF formula)

- Angina pectoris that requires the use of anti-anginal medication

- Ventricular arrhythmias except for benign premature ventricular contractions

- Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled
with medication

- Conduction abnormality requiring a pacemaker

- Valvular disease with document compromise in cardiac function

- Symptomatic pericarditis

- Patient has a history of cardiac dysfunction including any of the following:

- Myocardial infraction within the last 6 months, documented by persistent
elevated cardiac enzymes or persistent regional wall abnormalities on assessment
of LVEF function

- History of documented congestive heart failure (New York Heart Association
functional classification III-IV)

- Documented cardiomyopathy

- Patient has poorly controlled diabetes mellitus or steroid-induced diabetes mellitus
defined as a HgbA1C > 8% or a fasting plasma glucose level > 126 mg/dl.

- Patients without a history of diabetes mellitus need to have a fasting plasma glucose
level < 126 mg/dl.

- Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.,
active or uncontrolled infection) that could cause unacceptable safety risks or
compromise compliance with the protocol

• Significant symptomatic deterioration of lung function. If clinically indicated,
pulmonary function tests including measures of predicted lung volumes, DLco, O2
saturation at rest on room air should be considered to exclude pneumonitis or
pulmonary infiltrates.

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome, or small bowel resection). Patients with
unresolved diarrhea will be excluded as previously indicated

- Patients who have been treated with any hematopoietic colony-stimulating growth
factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin
or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be
continued

- Patients who are currently receiving treatment with medication with a known risk to
prolong the QT interval or inducing Torsades de Pointes and the treatment cannot
either be discontinued or switched to a different medication prior to starting study
drug. Please refer to Appendix E for a list of prohibited QT prolonging drugs with
risk of Torsades de Pointes. Please recognize that this list may not be all
inclusive.

- Patients receiving chronic treatment with steroids or another immunosuppressive
agent.

• Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways
diseases), eye drops or local injections (e.g. intr-articular) are allowed.

- Patients who have taken herbal medications and certain fruits within 7 days prior to
starting study drug. Herbal medications include, but are not limited to St. John's
wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA),
yohimbe, saw palmetto, and ginseng. Fruits include the CYP3A inhibitors Seville
oranges, grapefruit, pummelos, or exotic citrus fruits.

- Patients who are currently treated with drugs known to be moderate and strong
inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued
or switched to a different medication prior to starting study drug. Please refer to
Appendix B for a list of prohibited inhibitors and inducers of CYP3A. Please
recognize that this list may not be all inclusive. (Please note that co-treatment
with weak inhibitors of CYP3A is allowed).

- Patients who have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6
weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must
recover to a grade 1 toxicity excluding alopecia before starting the trial

- Patients who have received any continuous or intermittent small molecule therapeutics
(excluding monoclonal antibodies) ≤ 5 effective half- lives prior to starting study
drug or who have not recovered from side effects of such therapy

- Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
radiation for palliation ≤ 2 weeks prior to starting study drug or who have not
recovered from side effects of such therapy

- Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
who have not recovered from side effects of such therapy.

- Patients who are currently taking therapeutic doses of warfarin sodium or any other
coumadin-derivative anticoagulant.

- Women who are pregnant or breast feeding or adults of reproductive potential not
employing an effective method of birth control. Double barrier contraceptives must be
used through the trial by both sexes. Oral, implantable, or injectable contraceptives
may be affected by cytochrome P450 interactions, and are therefore not considered
effective for this study. Women of child-bearing potential must have a negative serum
pregnancy test ≤ 72 hours prior to initiating treatment.

- Women of child-bearing potential, defined as all women physiologically capable
of becoming pregnant, must use highly effective contraception during treatment
and for16 additional weeks after stopping treatment... The highly effective
contraception is defined as either:

1. True abstinence: When this is in line with the preferred and usual
lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation,
symptothermal, post-ovulation methods) and withdrawal are not acceptable
methods of contraception.

2. Sterilization: have had surgical bilateral oophorectomy (with or without
hysterectomy) or tubal ligation at least six weeks ago. In case of
oophorectomy alone, only when the reproductive status of the woman has been
confirmed by follow up hormone level assessment.

3. Male partner sterilization (with the appropriate post-vasectomy
documentation of the absence of sperm in the ejaculate). For female
subjects on the study, the vasectomized male partner should be the sole
partner for that patient.

4. Use of a combination of any two of the following (a+b):

1. Placement of an intrauterine device (IUD) or intrauterine system (IUS)

2. Barrier methods of contraception: Condom or Occlusive cap (diaphragm
or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal
suppository

- Oral contraception, injected or implanted hormonal methods are not allowed as
BKM120 potentially decreases the effectiveness of hormonal contraceptives.

- Fertile males, defined as all males physiologically capable of conceiving
offspring must use condom during treatment and for an additional 16 weeks after
stopping treatment.

- Female partner of male study subject should use highly effective contraception
during dosing of any study agent and for 16 weeks after final dose of study
therapy.

- Known diagnosis of human immunodeficiency virus (HIV) infection

- History of another malignancy within 3 years, except cured basal cell carcinoma of
the skin or excised carcinoma in situ of the cervix

- Patient is unable or unwilling to abide by the study protocol or cooperate fully with
the investigator